Business Wire07.16.21
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the company’s NUsurface Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy. The results were presented at the American Orthopedic Society for Sports Medicine-Arthroscopy Association of North America Combined 2021 Annual Meeting in Nashville.
The NUsurface Implant is the first “artificial meniscus” to be marketed in Europe and is currently under review by the U.S. Food & Drug Administration (FDA). The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint. It was granted a Breakthrough Device Designation from the FDA in 2019.
“The MERCURY study showed that patients who received the NUsurface Implant experienced statistically superior pain relief as early as six months that continued through the two-year study period, compared to patients receiving non-surgical care alone,” said Wayne Gersoff, M.D., a MERCURY investigator from Advanced Orthopedic & Sports Medicine Specialists in Denver, who presented the study results. “There is a significant need for new treatment options for patients who have persistent knee pain following a meniscectomy, which the NUsurface Implant may address.”
The MERCURY Study is the longest and most extensive study of a meniscus implant in the world, enrolling 242 patients experiencing persistent knee pain after a previous meniscectomy: 176 were treated with the NUsurface Implant and 66 with non-surgical therapy. Results of the study include:
The abstract, “Superior Improvements in Knee Pain and Function with a Novel Synthetic Medial Meniscus Replacement Implant Compared to Nonsurgical Care in Subjects with Knee Pain Following Partial Meniscectomy: Two-year Results from Two Prospective US Clinical Trials” was selected to be featured in an AOSSM-AANA meeting press release.
“We’re gratified that AOSSM-AANA selected the MERCURY study results as one of the presentations to highlight—a reflection of the fact that current treatment options for post-arthroscopic partial meniscectomy knee pain are limited, especially for patients considered too young for knee replacement,” said Ted Davis, president and CEO of Active Implants. “The two-year results of the study demonstrate that the NUsurface Implant not only reduces pain but may also help preserve cartilage on the medial femoral condyle.”
The NUsurface Implant is the first “artificial meniscus” to be marketed in Europe and is currently under review by the U.S. Food & Drug Administration (FDA). The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint. It was granted a Breakthrough Device Designation from the FDA in 2019.
“The MERCURY study showed that patients who received the NUsurface Implant experienced statistically superior pain relief as early as six months that continued through the two-year study period, compared to patients receiving non-surgical care alone,” said Wayne Gersoff, M.D., a MERCURY investigator from Advanced Orthopedic & Sports Medicine Specialists in Denver, who presented the study results. “There is a significant need for new treatment options for patients who have persistent knee pain following a meniscectomy, which the NUsurface Implant may address.”
The MERCURY Study is the longest and most extensive study of a meniscus implant in the world, enrolling 242 patients experiencing persistent knee pain after a previous meniscectomy: 176 were treated with the NUsurface Implant and 66 with non-surgical therapy. Results of the study include:
- 84 percent of patients treated with the NUsurface Implant experienced a 10-point improvement from baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain, which is considered the minimum clinically relevant improvement in pain and function.
- 89 percent of patients who received the NUsurface Implant completed 24 months of follow-up.
- Patients with replacement implants achieved superior results the second time; 70 percent of patients used one implant and 20 percent received a replacement implant.
- Obese and older patients had the highest response rates.
- MRI evidence showed the NUsurface Implant may preserve femoral cartilage, while the control patients showed evidence of significant cartilage deterioration.
The abstract, “Superior Improvements in Knee Pain and Function with a Novel Synthetic Medial Meniscus Replacement Implant Compared to Nonsurgical Care in Subjects with Knee Pain Following Partial Meniscectomy: Two-year Results from Two Prospective US Clinical Trials” was selected to be featured in an AOSSM-AANA meeting press release.
“We’re gratified that AOSSM-AANA selected the MERCURY study results as one of the presentations to highlight—a reflection of the fact that current treatment options for post-arthroscopic partial meniscectomy knee pain are limited, especially for patients considered too young for knee replacement,” said Ted Davis, president and CEO of Active Implants. “The two-year results of the study demonstrate that the NUsurface Implant not only reduces pain but may also help preserve cartilage on the medial femoral condyle.”
